PDCD1 and breast carcinoma: In line with this finding, our recent study in a murine breast cancer model revealed that anti-PD1 therapy, beside enhancing T cells activity, activates NK cells, increasing expression of FasL, NKG2D, production of IFN-γ while simultaneously reducing inhibitory markers such as Foxp3 and IL-10 [42].